Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM +2.97%92 3-1 Month Momentum % is 15.57% as of Aug. 11, 2026. GuruFocus rates LTS:0JDM with a GF Score™ of 92/100 and a GF Value™ of $245.97 (Fairly Valued). The stock has 8 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 76.89% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-11), IQVIA Holdings's 3-1 Month Momentum % is 15.57%.
The industry rank for IQVIA Holdings's 3-1 Month Momentum % or its related term are showing as below:
LTS:0JDM's 3-1 Month Momentum % is ranked better than 76.89% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -4.365
vs LTS:0JDM: 15.57
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
IQVIA Holdings 3-1 Month Momentum % Related Terms
LTS:0JDM vs WAT, NTRA, A: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (LTS:0JDM) has a 3-1 Month Momentum % of 15.57% as of Aug. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on IQVIA Holdings and its competitors. According to the industry distribution chart, IQVIA Holdings ranks #49 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 23.1%.
Is IQVIA Holdings' 3-1 Month Momentum % too high?
IQVIA Holdings' current 3-1 Month Momentum % is 15.57%. Based on the distribution chart, IQVIA Holdings ranks #49 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IQVIA Holdings has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' 3-1 Month Momentum % compare to WAT and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #49 out of 212 companies for 3-1 Month Momentum %. This places IQVIA Holdings in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on IQVIA Holdings and its competitors. IQVIA Holdings's current 3-1 Month Momentum % is 15.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Fairly Valued. The stock's GF Value™ is $245.97, compared to a current price of $242.75 — trading 1.3% below its estimated fair value. The current 3-1 Month Momentum % is 15.57%. IQVIA Holdings' overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current 3-1 Month Momentum % is 15.57% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $242.75 is trading 1.3% below its estimated GF Value™ of $245.97.
GuruFocus considers IQVIA Holdings to be Fairly Valued.
Key valuation signals for LTS:0JDM:
3-1 Month Momentum %: 15.57%
GF Value™: $245.97 vs. price of $242.75 (1.3% below fair value)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
92GF Score
Get the complete analysis for LTS:0JDM
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
